Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | RPA1 | P27694 | 7/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21555940 | 0.84 | GAA (0.52) | L3MBTL1GAARPA1CNR1ALDH1A1 | |
| SCHEMBL11300411 | 0.84 | PTGS2 (0.50) | GAACNR1ALDH1A1MAPTLMNA | |
| SCHEMBL1303442 | 0.82 | CYP1A2 (0.56) | L3MBTL1ALDH1A1MAPTLMNA | |
| SCHEMBL2201331 | 0.78 | LMNA (0.60) | L3MBTL1GAARPA1SIGMAR1CNR1 | |
| SCHEMBL1303088 | 0.78 | POLB (0.40) | L3MBTL1ALDH1A1MAPTLMNA | |
| SCHEMBL10250947 | 0.78 | RAB9A (0.47) | L3MBTL1ALDH1A1MAPT | |
| SCHEMBL9779069 | 0.77 | CYP1A2 (0.56) | ALDH1A1MAPTLMNA | |
| SCHEMBL314751 | 0.75 | SMN1; SMN2 (0.45) | L3MBTL1ALDH1A1MAPT | |
| SCHEMBL3015820 | 0.75 | L3MBTL1 (0.55) | L3MBTL1GAAALDH1A1MAPTLMNA | |
| SCHEMBL20406831 | 0.75 | STAT1 (0.51) | L3MBTL1GAAALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093251-B2 | Nitrogen-containing heterocyclic compounds and thrombopoietin receptor activators | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-01-10 | — | — | US | disclosed |
| US-8093251-B2 | Nitrogen-containing heterocyclic compounds and thrombopoietin receptor activators | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-01-10 | — | — | US | disclosed |
| US-8026368-B2 | Hydrazide compounds and thrombopoietin receptor activators | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2011-09-27 | — | — | US | disclosed |
| US-20090253751-A1 | HYDRAZIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-10-08 | — | — | US | disclosed |
| US-20090198060-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-08-06 | — | — | US | disclosed |
| US-20090198060-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-08-06 | — | — | US | disclosed |
| EP-2025671-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | Nissan Chemical Industries, Ltd. (JP) | 2009-02-18 | — | — | EP | disclosed |
| EP-1947101-A1 | HYDRAZIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | Nissan Chemical Industries, Ltd. (JP) | 2008-07-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090198060-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | TEK, MPL, IL1RN | L3MBTL1 1389/4885GAA 2942/4885RPA1 4002/4885 |
| US-20090253751-A1 | HYDRAZIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | TEK, THPO, PTAFR | L3MBTL1 2628/4885GAA 1382/4885RPA1 4554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.